US2007073043A1PendingUtilityA1

Process for producing humanized chimera antibody

Assignee: KYOWA HAKKO KOGYO KKPriority: Sep 18, 1991Filed: Sep 19, 2005Published: Mar 29, 2007
Est. expirySep 18, 2011(expired)· nominal 20-yr term from priority
C07K 2317/24A61P 35/00A61K 2039/505C07K 2317/734C07K 16/18A61K 38/00C07K 16/3084C07K 16/462C07K 2319/00C07K 2317/732C07K 2319/02
63
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A humanized chimera antibody, a pharmaceutical composition comprising a humanized chimera antibody and a pharmaceutically acceptable carrier, and a method of treating cancer which comprises administering to a patient a pharmaceutically acceptable amount of the humanized chimera antibody, are disclosed.

Claims

exact text as granted — not AI-modified
1 . A process for producing humanized antibody which comprises the steps of: 
 (1) constructing a cassette vector by inserting a cDNA coding for a heavy chain constant region (Cγ1) of human antibody into an expression vector for animal cell use and establishing a cloning site in the upstream region of the heavy chain constant region (Cγ1) of said cassette vector for inserting a cDNA which encodes a heavy chain variable region including CDRs of nonhuman animal antibody;    (2) digesting a cDNA coding for the heavy chain variable region of humanized antibody with restriction enzymes;    (3) inserting said cDNA coding for the heavy chain variable region of humanized antibody into the cassette vector, using a synthetic DNA which comprises a base sequence corresponding to the 5′end side of said heavy chain constant region of human antibody as defined by the 31st to 43rd base in SEQ ID NO:13 and a base sequence corresponding to the 3′-end side of said heavy chain variable region including CDRs of nonhuman animal antibody and is possessed of the restriction enzyme recognition sites on both of its ends, thereby constructing a humanized antibody heavy chain expression vector in which said cDNA coding for the heavy chain constant region of human antibody and said cDNA coding for the heavy chain variable region including CDRs of nonhuman animal antibody are linked together through said synthetic DNA;    (4) constructing a cassette vector by inserting a cDNA coding for a light chain constant region (Cκ) of human antibody into an expression vector for animal cell use and establishing a cloning site in the upstream region of the light chain constant region (Cκ) of said cassette vector for inserting a cDNA which encodes a light chain variable region including CDRs of nonhuman animal antibody;    (5) digesting a cDNA coding for the light chain variable region including CDRs of nonhuman animal antibody with restriction enzymes;    (6) inserting said cDNA coding for a light chain variable region including CDRs of nonhuman animal antibody into the cassette vector, using a synthetic DNA which comprises a base sequence corresponding to the 5′-end side of said light chain constant region of human antibody as defined by the 48th to 61st base in SEQ ID NO:15 and a base sequence corresponding to the 3′-end side of said light chain variable region including CDRs of nonhuman animal antibody and is possessed of the restriction enzyme recognition sites on both of its ends, thereby constructing a humanized chimera antibody light chain expression vector in which said cDNA coding for the light chain constant region of human antibody and said cDNA coding for the light chain variable region including cDRs of nonhuman animal antibody are linked together through said synthetic DNA;    (7) introducing these expression vectors into host cells to obtain a transformant; and    (8) culturing said transformant in an appropriate culture medium, thereby allowing the transformant to produce and accumulate a humanized antibody, and collecting said humanized antibody from the resulting culture broth.    
     
     
         2 . The process according to  claim 1 , wherein the synthetic DNA used for the heavy chain has the DNA sequence showing SEQ ID NO 13.  
     
     
         3 . The process according to  claim 1 , wherein the synthetic DNA used for the light chain has the DNA sequence showing SEQ ID NO: 15.

Join the waitlist — get patent alerts

Track US2007073043A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.